Rescue effect of daily infusions with Legalon® SIL in Hepatitis C Virus-infected patients who are incomplete responders to standard pegylated interferon/ribavirin (dual therapy) or pegylated interferon/ribavirin plus a protease inhibitor (triple therapy): a randomized, controlled, parallel-group, multicenter clinical trial.
Phase of Trial: Phase II
Latest Information Update: 28 May 2014
Price : $35 *
At a glance
- Drugs Silibinin (Primary) ; Hepatitis C protease inhibitors; Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms SANTE
- Sponsors Rottapharm Madaus
- 10 May 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
- 18 Sep 2013 New trial record